Under terms of the new partnership, Phytonet will be the distributor of the Bimuno GOS, both in powder and syrup formats, in Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Greece, Kosovo, Montenegro, North Macedonia, Romania, Serbia, Slovenia, Switzerland, Turkey and Japan.
Dr Frederic Narbel, VP of Sales B2B at Clasado, commented on the growing global demand for prebiotics across the globe.
“Bimuno GOS stands out clearly on the market as the most studied prebiotic of its kind, backed by more than 110 scientific publications, including more than 20 clinical trials. Our new agreement with Phytonet, covering an expansive range of territories, makes it more accessible than ever before.
“Phytonet's dedication to scientific excellence, coupled with their established presence in these markets, places them in an excellent position to develop finished products incorporating Bimuno GOS.
"Their proficiency as a contract manufacturer further enhances their capabilities, making them an ideal commercial partner across the numerous territories. In collaboration, we are poised to empower brands and formulators within these regions, delivering the benefits of Bimuno GOS backed by rigorous research.”
As the most studied commercially available galactooligosaccharide, Bimuno GOS' safety and efficacy are supported by over 110 scientific publications, including more than 20 clinical trials, making it the most comprehensively studied prebiotic of its kind.
The scientific backing underscores its influence on various aspects of gastrointestinal, digestive, immune, and cognitive health.
What's more, according to research firm Mordor Intelligence, the European prebiotics market is projected to experience a robust compound annual growth rate of over 7%, powered by growing consumer demand.
Just last Spring, the European Food Safety Authority (EFSA) gave the thumbs up to extending the use of Bimuno’s galactooligosaccharises (GOS) as a novel food for use in special medical purposes (FSMP).
The opinion by the food authority paved the way for Bimuno GOS to be used for the dietary management of impaired gastrointestinal issues in hospitalised patients.
Headquartered in Switzerland with affiliates in several countries, Phyonet's portfolio includes pro and prebiotics, pharmaceutical ingredients, plant extracts, vitamins and minerals.
The technical team at Phytonet comprises experienced physicians, chemists, nutritionists and healthcare professionals, lending their deep expertise to the development of health and wellbeing solutions. Supporting its customers from concept to completion, Phytonet's formulation prowess ensures tailor-made products that resonate with the needs of today’s consumer.
Dr. Cem Aydogan, Founder & CEO of Phytonet, adds: "We are excited to partner with Clasado Biosciences to deliver evidence-backed microbiome modulating solutions to our customers. Bimuno GOS aligns perfectly with our commitment to quality and scientific rigor and makes a fantastic addition to our ingredient portfolio."